HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Speaker at Drug Delivery Events - Ernst Wagner
Ludwig-Maximilians-Universitat Munich, Germany
Title : Chameleon nanocarriers for dynamic delivery of RNA Medicines

Abstract:

Twenty two RNA therapies reached the medical market by Q1 2023. Targeted intracellular delivery remains the key requirement. For refinements of nanocarriers we focus on a bioinspired, sequence-defined process including (i) artificial amino acids (ii) precise assembly into xenopeptide sequences by solid phase-assisted synthesis (iii) screening for delivery and selection of top candidates. A recent chemical evolution library combined aminoethylene amino acids as polar protonatable units with novel lipo amino fatty acids (LAFs) as hydrophobic protonatable motifs. These novel double pH-responsive nucleic acid carriers utilize intracellular delivery mechanisms of both cationizable lipids and cationic polymers. The endosomal pH-dependent tunable polarity of LAF was successfully implemented by a central tertiary amine, which disrupts the hydrophobic character once protonated, resulting in drastic pH-dependent change in the logarithmic (octanol/water) distribution logD from around +1 (pH 7.4) to -1 (pH 5.5). This “molecular chameleon character” turned out to be advantageous for mRNA, siRNA or CRISPER/Cas9 sgRNA delivery. The efficiency of best performers was up to several 100-fold higher compared to previous carriers. Transfection activity of mRNA lipoplexes was maintained even in the presence of 90% serum and at extremely low dosage of 3 pg mRNA (~2 nanoparticles/cell), in the range of the viral potency. mRNA lipoplexes showed great in vivo performance in mice with high expression levels in the spleen, tumor, lung, and liver upon intravenous administration of 1 µg luciferase mRNA.

Audience Take Away Notes:

  • Explains how bioinspired chemical evolution can be applied to optimize RNA carriers
  • Chemical evolution is based on precise sequences of defined building blocks
  • Sequence-defined xenopeptides are assembled by solid-phase synthesis using artificial amino acids
  • Intracellular delivery transporters must be dynamic to be efficient on nanoparticle basis

Biography:

Dr. Wagner is full professor of Pharmaceutical Biotechnology at LMU since 2001 and member of the Munich Center for Nanoscience. He coordinates ‘Biomedical Nanotechnologies’ of the Excellence Cluster NIM. After a PhD from TU Vienna and postdoc at ETH Zürich, he was Group Leader at the IMP Vienna (1987-1995) and Director for Cancer Vaccines at BoehringerIngelheim Austria (1992-2001). Dr. Wagner has authored >403 publications (h-index 72). He is Board member of the German Society for Gene Therapy, Committee member of ASGCT, and BSA member of CRS. He is Editor of Pharmaceutical Research and Editor-in-Chief of The Journal of Gene Medicine.

Watsapp